Several brokerages have updated their recommendations and price targets on shares of Aimmune Therapeutics (NASDAQ: AIMT) in the last few weeks:

  • 12/5/2017 – Aimmune Therapeutics had its price target raised by analysts at Piper Jaffray Companies from $38.00 to $60.00. They now have an “overweight” rating on the stock.
  • 12/1/2017 – Aimmune Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 12/1/2017 – Aimmune Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $70.00 price target on the stock.
  • 11/20/2017 – Aimmune Therapeutics is now covered by analysts at Roth Capital. They set a “buy” rating and a $60.00 price target on the stock.
  • 11/8/2017 – Aimmune Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $34.00 price target on the stock. According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
  • 10/23/2017 – Aimmune Therapeutics had its price target raised by analysts at Credit Suisse Group AG from $36.00 to $45.00. They now have an “outperform” rating on the stock.
  • 10/23/2017 – Aimmune Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $70.00 price target on the stock, up previously from $42.00.
  • 10/21/2017 – Aimmune Therapeutics was given a new $38.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 10/16/2017 – Aimmune Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Aimmune Therapeutics, Inc. (AIMT) traded up $0.08 during mid-day trading on Wednesday, hitting $36.28. The company had a trading volume of 300,400 shares, compared to its average volume of 355,100. Aimmune Therapeutics, Inc. has a 1-year low of $15.97 and a 1-year high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. analysts anticipate that Aimmune Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

In related news, insider Mary M. Rozenman sold 30,000 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $22.50, for a total value of $675,000.00. Following the completion of the sale, the insider now directly owns 30,129 shares in the company, valued at approximately $677,902.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Susan E. Barrowcliffe sold 20,000 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.00, for a total value of $500,000.00. Following the completion of the sale, the insider now owns 20,000 shares of the company’s stock, valued at $500,000. The disclosure for this sale can be found here. Insiders sold a total of 303,080 shares of company stock valued at $8,134,414 over the last 90 days. 17.59% of the stock is currently owned by corporate insiders.

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.